Printer Friendly

UPJOHN ENDORSES EC DECISION ON HALCION

 UPJOHN ENDORSES EC DECISION ON HALCION
 KALAMAZOO, Mich., Dec. 12 /PRNewswire/ -- The Upjohn Company


(NYSE: UPJ) announced today that it is pleased with the opinion issued by the European Community's Committee for Proprietary Medicinal Products (CPMP) regarding use of Halcion Tablets in European Community (EC) member states. Halcion is the world's leading prescription sleeping medication.
 The CPMP announced following its Dec. 11 meeting that it supports the Halcion labelling and packaging changes that it recommended in October, while confirming the "absolute importance" of short-term use of the product. In addition, the committee directed its working group to expand its review from Halcion to all short-acting sleeping medications.
 "We believe that the CPMP's opinion confirms our confidence in the safety and efficacy of Halcion," said Theodore Cooper, M.D., Ph.D., Upjohn's Chairman and Chief Executive Officer. "We encourage regulatory authorities across the European Community to consider these recommendations in future reviews of short-acting hypnotics, including Halcion."
 According to EC legislation, the CPMP must immediately inform member states of its Halcion opinion. Member states, in turn, are required to decide on a course of action within 60 days. While the CPMP opinions are not binding on national regulatory authorities, they are intended to encourage a coordinated approach by member states to regulatory decisions.
 The Upjohn Company is a worldwide, research-based provider of human health-care products, animal health products, agronomic and vegetable seeds and specialty chemicals. Headquartered in Kalamazoo, the company has been dedicated to improving health and nutrition for more than a century.
 -0- 12/12/91
 /CONTACT: Kaye Bennett of The Upjohn Company, 616-323-4224/
 (UPJ) CO: The Upjohn Company ST: Michigan IN: MTC SU:


ML -- DE003 -- 1762 12/12/91 08:13 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 12, 1991
Words:283
Previous Article:JACOBS RECEIVES CONTRACT FOR EXXON AROMATICS PROJECTS
Next Article:AMERICAN SUPERCONDUCTOR INITIAL PUBLIC OFFERING OF 1,670,000 SHARES DECLARED EFFECTIVE
Topics:


Related Articles
UPJOHN ANNOUNCES NEW U.S. PACKAGING AND LABELING FOR HALCION
UPJOHN TO DEFEND AND INDEMNIFY PHYSICIANS WHO PRESCRIBE HALCION
UPJOHN ENDORSES EC DECISION ON HALCION
UPJOHN RESPONSE TO HALCION TV CHARGES
UPJOHN APPEALS HALCION SUSPENSION TO U.K. MEDICINES COMMISSION
SPAIN TAKES ACTION ON HALCION
ADVISORY COMMISSION RECOMMENDS HALCION RETURN TO U.K. MARKET
UPJOHN WINS HALCION CASE
UPJOHN WINS APPEAL IN TEXAS HALCION CASE
UPJOHN WINS MISSOURI HALCION CASE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters